Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease

Annals of Clinical and Laboratory Science

Volumn 36, Issue 4, 2006, Pages 449-454

  Sahin, Mehmet ^a   Arslan, Cagatay ^a   Naziroglu, Mustafa ^a,b   Tunc, S Ercan ^a   Demirci, Mustafa ^a   Sutcu, Recep ^a   Yilmaz, Nigar ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

Asymmetric dimethylarginine (ADMA); Behcet's disease; Endothelial inflammation; Nitric oxide; Vasculitis

Indexed keywords

DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; RISK FACTOR; SPECTROPHOTOMETRY; SYSTEMIC VASCULITIS; VASCULAR DISEASE;

ADULT; ARGININE; BEHCET SYNDROME; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VASCULITIS;

EID: 33751223566     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Behcet H, Uber rezidivierende Apthose, durch ein Virus verursachte geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937;105:1152-1157.
2. Shapiro MA, Behcet's Disease: Immune Process and the Potential Impact of Nutritional Supplementation and Pharmaco-nutrition. Angelfire, New York, 1994; pp 1-47.
3. Kokcam I, Naziroglu M. Effects of vitamin E supplementation on blood antioxidant levels in patients with Behcet's disease. Clin Biochem 2002;35:633-639.
4. Evereklioglu C, Turkoz Y, Er H, Inaloz HS, Ozbek E, Cekmen M. Increased nitric oxide production in patients with Behcet's disease: is it a new activity marker? J Am Acad Dermatol. 2002;46:50-54.
5. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome. J Am Coll Cardiol 2001;37:517-520.
6. Cekmen M, Evereklioglu C, Er H, Inaloz HS, Doganay S, Turkoz Y, Ozerol IH. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome. Int J Dermatol 2003;42:870-875.
7. Evereklioglu C. Managing the symptoms of Behcet's disease. Expert Opin Pharmacother 2004;5:317-328.
8. Halliwell B, Gutteridge JM. Free radicals in biology and medicine. Clarendon, Oxford, 1999; pp 1-543.
9. Moshage H. Nitric oxide determinations: much ado about NO-thing? Clin Chem 1997;43:553-556.
10. Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 2005;108:225-256.
11. Perticone F, Ceravolo R, Pujia A, Ventura G, Lacopino S. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-196.
12. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005;46:518-523.
13. MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994;112:43-48.
14. Boger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 2005;43:1124-1129.
15. Faraci FM, Brian JE Jr, Heistadt DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995;269:H1522-1527.
16. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-2074.
17. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-1080.
18. Holm T, Aukrust P, Aagaard E, Ueland T, Haugstad T, Kjekshus J, Simonsen S Froland SS, Gullestad L, Andreassen AK. Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension. Transplantation 2002;74:1395-1400.
19. Buldanlioglu S, Turkmen S, Ayabakan HB, Venice N, Vardar M, Dogan S, Mercan E. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behcet's disease. Br J Dermatol 2005;153:526-530.
20. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996;119:1533-1540.
21. Nathan C, Xie OW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994;269:13725-13728.
22. Kiraz S, Ertenli I, Calguneri M, Ozturk MA, Haznedaroglu IC, Altun B, Erman M, Celik I. Interactions of nitric oxide and superoxide dismutase in Behcet's disease. Clin Exp Rheumatol 2001;19:S25-29.
23. Orem A, Vanizor B, Cimsit G. Kiran E, Deger O, Malkoc M. Decreased nitric oxide production in patients with Behcet's disease. Dermatology 1999;198:33-36.
24. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. PNAS USA 1991;88:4651-4655.
25. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992;90:1168-1172.
26. Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, Bruckdorfer KR. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology 2006;45:676-684.
27. Mallamaci F, Tripepi G, Malberti F, Cutrupi S, Malatino LS, Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005;67:2330-2337.
28. Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126-136.
29. Boger RH, Bode-Boger SM. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost 2000;26:539-545.
30. Ueda S. Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, Imaizumi T. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine and dimethylaminohydrolase. Circ Res 2003;92:226-233.
31. Pronai L, Ichikawa Y, Kakazawa H, Arimori S. Superoxide scavenging activity of leukocytes in rheumatoid arthritis and Behcet's disease. Tokai J Exp Clin Med 1990;15:93-97.